# Study of F527 in Patients With Relapsed or Refractory Lymphoma

> **NCT05293028** · PHASE1 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 82 (estimated)

## Conditions studied

- Relapsed/Refractory Lymphoma

## Interventions

- **DRUG:** F527

## Key facts

- **NCT ID:** NCT05293028
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-20
- **Primary completion:** 2023-11-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2022-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293028, "Study of F527 in Patients With Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05293028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*